Comparative Outcomes of HBV-Related vs. HCV-Related Hepatocellular Carcinoma Under Targeted Therapy: A Retrospective Study

Document Type

Conference Proceeding

Publication Date

6-2-2025

Publication Title

Journal of Clinical Oncology

Abstract

Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide, with hepatitis B virus (HBV) and hepatitis C virus (HCV) as primary etiological factors. This study compares the clinical outcomes of HBV-related and HCV-related HCC patients undergoing targeted therapy. Methods: This retrospective cohort study included patients diagnosed with early stage HBV-related or HCV-related HCC between 2010 and 2020, who underwent targeted therapy with Cabozantinib, Lenvatinib, Sorafenib, and Regorafenib. Data was obtained from the TriNetX database. A total of 726 patients with HBV and 726 with HCV were matched for demographic and clinical characteristics. Baseline characteristics, follow-up durations, all-cause mortality, and overall survival rates were analyzed using descriptive statistics, Kaplan-Meier curves, and measures of association. Results: Before matching, HCV patients had a mean age of 62.8 ± 8.11 years, while HBV patients had a mean age of 64.7 ± 9.34 years . Post-matching, age and gender distributions were balanced, with no significant differences. Median follow-up was longer in HCV patients (333 days, IQR: 786) than HBV patients (215 days, IQR: 524). All-cause mortality risks were comparable, with a risk ratio (RR) of 0.946 (95% CI: 0.88–1.017, p = 0.1318). Kaplan-Meier analysis showed significantly better overall survival for HCV patients, with a median survival of 416 days versus 282 days in HBV patients (HR: 0.793, 95% CI: 0.699–0.9, p = 0.0003). Survival probabilities at the end of the study period were 11.11% for HCV and 9.56% for HBV patients. Conclusions: HCV-related HCC patients demonstrated longer follow-up durations and better overall survival compared to HBV-related HCC patients under targeted therapy. These findings underscore the need for tailored treatment approaches to optimize outcomes for HBV and HCV patients with HCC.

First Page

e16319

Comments

2025 ASCO (American Society of Clinical Oncology) Annual Meeting, May 30 - June 3, 2025, Chicago, IL

Last Page

e16319

DOI

10.1200/JCO.2025.43.16_suppl.e16319

Link to Full Text

Share

COinS